A clinical trial update dated September 3, 2026 reports on a study titled "Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors." The trial, registered as NCT05687123, is listed as a Phase 1 study. Its current status is recruiting, meaning the study is actively enrolling participants at this time.
This trial evaluates the addition of sunitinib malate to Lutetium Lu 177 Dotatate, known by the brand name Lutathera, in the context of pancreatic neuroendocrine tumors. As a Phase 1 study, its primary focus at this stage is typically centered on early-phase clinical investigation. No outcome data, efficacy findings, or safety results have been reported in this update.
Somatostatin, referenced in connection with this therapeutic area, currently carries a regulatory status of unapproved research use. Readers should note that trial status can change as recruitment progresses, and further updates may follow as the study advances through its phases. Details on eligibility, design, and objectives can be found through the official trial registry listing.
For additional context on somatostatin and its research background, readers can consult the compound overview.